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Summary
Background and objectives Renal function is an important predictor of survival in cirrhosis and liver trans-
plantation. GFR estimates using serum cystatin C (CysC) are proposed as better predictors of renal function
than ones on the basis of serum creatinine (Cr). Our aims were: (1) evaluate correlations between serum
CysC and different methods of creatinine measurements; (2) compare CysC and Cr GFR formulas with
51Cr-EDTA; and (3) evaluate liver-related parameters potentially influencing GFR.
Design, setting, participants, & measurements 254 blood samples in 65 patients with cirrhosis correlating
CysC with four Cr methods were used; another 74 patients comparing 51Cr-EDTA GFR to Modification of
Diet in Renal Disease and Larsson and Hoek formulas for CysC were also included. Agreement was as-
sessed using Bland-Altman plots and concordance correlation coefficients. Multivariate linear regression
analysis was used for GFR predictors.
Results Serum CysC correlated modestly with O’Leary modified Jaffe, compensated kinetic Jaffe, enzymatic
creatinine, and standard kinetic Jaffe 0.72/0.71/0.72/0.72 (all P  0.001). Bland-Altman agreement with
51Cr-EDTA GFR was poor; the best agreement was Modification of Diet in Renal Disease (concordance 0.61;
95% CI, 0.47 to 0.71); the worst agreement was the Hoek formula (concordance 0.46; 95% CI, 0.27 to 0.61). A
new GFR formula including the Child-Pugh score improved the accuracy of Cr GFR formulas compared
with 51Cr-EDTA GFR.
Conclusions Estimated GFR in cirrhosis is not better with CysC formulas compared with creatinine ones:
specific formulas may be necessary.
Clin J Am Soc Nephrol 6: 84–92, 2011. doi: 10.2215/CJN.03400410
Introduction
Renal dysfunction is a well established predictor of in-
creased mortality in both acute liver failure and cirrho-
sis, particularly after the development of complications,
such as sepsis (1), and after liver transplantation (2).
Serum creatinine (Cr) is only an indirect marker of renal
function, i.e., of GFR. Measurement of Cr suffers from a
variety of interferences and is not standardized (3,4).We
and others previously reported (4,5) that different meth-
ods used for measuring Cr give significantly different
values. Recently we found a lack of agreement in creat-
inine values (6) between different laboratories that used
the same method of measurement. We also reported (7)
that Cr values significantly overestimate renal function
in women. Other factors affecting Cr are also known (8).
Thus the most frequently used GFR formulas (8), the
Cockcroft-Gault (C-G) (9) and Modification of Diet in
Renal Disease (MDRD) (10), use several corrections for
age, gender, ethnicity, and body weight. Different cre-
atinine-based formulas were evaluated (11) in 1447 pa-
tients with cirrhosis, all transplant candidates, using
125I-iothalamate clearance as a reference standard; the
four-, five-, and six-variableMDRD equations were sim-
ilar and had greater accuracy than the C-G formula, but
the concordance with 125I-iothalamate clearance was
lower than the equivalent MDRD estimations in other
populations.
Inulin clearance and other direct methods using in-
jected exogenous radiolabeled substances (51Cr-
EDTA,125I-iothalamate, and 99mTc-DTPA) are the
most accurate to assess renal function. The 51Cr-
EDTA method is an accepted substitute of the “gold
standard” inulin clearance (12).
Serum cystatin C (CysC) is a low molecular weight
protein functioning as an extracellular inhibitor of cys-
teine proteases (13). CysC is freely filtered by the renal
glomeruli and subsequently metabolized in the proxi-
mal tubules. Given these features and the reported in-
dependence of CysC from age, gender, and body com-
position (14), it has been considered a more sensitive
indicator of renal function compared with Cr in several
disease groups (15) including cirrhosis (16–18).
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Thus several CysC-based GFR equations have been
derived (19), all in nonliver disease patients. Despite
being more accurate than Cr-based formulas (15),
they still lacked significant correlation with direct
methods of GFR estimation. To date only one study
evaluated (20) CysC GFR, using the Larsson et al. (21)
and Hoek et al. (22) formulas in patients with cirrho-
sis, comparing them with MDRD (10) and C-G (9).
Inulin clearance was the gold standard. The CysC
formulas were more accurate than the Cr formulas
but had significantly different values of GFR in com-
parison with inulin clearance.
In cirrhosis, CysC has been proposed as a marker of
liver disease stage (23). Significant differences were
found in CysC values but not Cr values between Child-
Pugh class A, B, and C patients (18). Cr and CysC
concentrations correlated well with the severity of liver
disease in 180 patients (24), but a gold standard to assess
renal function was not used. Increased CysC values in
cirrhosis may be related to increased production, sec-
ondary to active inflammatory and fibrotic processes
(25), decreased renal function, or both.
Our aims were: (1) to assess correlations between
serum CysC and different Cr measurement methods
and to evaluate whether bilirubin (Bil) concentration
affects CysC; (2) to compare “true” GFR using a gold
standard method and estimated GFR (eGFR) using Cr
and CysC; and (3) to investigate whether a new for-
mula to estimate GFR in cirrhosis using parameters
related to liver function could be derived.
Materials and Methods
We used 256 consecutive blood samples obtained
during routine clinical care from 65 patients with cirrho-
sis, at the Royal Free Hospital, being part of a previously
reported cohort (4) and samples from a separate cohort
of 74 patients, with cirrhosis candidates for liver trans-
plantation who had 51Cr-EDTA GFR measurement
(C51Cr-EDTA) as pretransplant assessment. We com-
pared C51Cr-EDTAwith Cr and CysC-GFR formulas. In
the 74 transplant candidates, stepwise multivariate lin-
ear regression analysis was used to identify any liver
disease-specific factors influencing renal function to de-
rive a new GFR model. We tested bilirubin interference
with CysC with dilution/titration curves in blood sam-
ples taken from five patients with a median bilirubin of
582 mol/L (range, 303 to 639 mol/L).
Clinical, hematologic, and biochemical data were
collected on the day of the C51Cr-EDTA. The Child-
Pugh (CPT) (26) and Model for End-stage Liver Dis-
ease (MELD) (http://www.unos.org) scoring systems
were calculated. Cirrhosis, ascites, encephalopathy,
and hepatocellular carcinoma (HCC) were diagnosed
by clinical, imaging, and histologic criteria. Patients
consented for the 51Cr-EDTA clearance results to be
used. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki.
Analyses in the First Cohort
For serum creatinine measurement we evaluated
four commonly used methods in the UK and the USA
(27): (1) O’Leary modified Jaffe (mJCr): potassium
ferricyanide was used to oxidize bilirubin to biliver-
din (prestep), and an increase in absorbance was mea-
sured at 505 nm and blanking at 570 nm; (2) compen-
sated (rate blanked) kinetic Jaffe (cJCr): measured
increase in absorbance at 505 nm with blanking at 570
nm; (3) enzymatic creatinine (ECr): we used a creati-
ninase/creatinase/sarcosine oxidase system with de-
tection at 546 nm and absorbance blanking at 700 nm,
and a Roche Modular P unit (Roche Diagnostics, Ltd.,
Lewes, UK) was used for all three assays, calibrated
using a lyophilized human serum-based Cfas calibra-
tor (Roche Diagnostics) standardized using the isotope
dilution mass spectrometry method; and (4) standard
kinetic Jaffe (JCr): performed on an Olympus AU2700
analyzer (Olympus Diagnostic Systems, Southall, UK);
calibration was by the manufacturer’s recommended
Olympus System calibrator (traceable to the National
Institute of Standards and Technology Standard Refer-
ence Material [909b, level 2]). It measures increased ab-
sorbance at 520 nm and blanking at 800 nm.
CysC was analyzed by immunonephelometry us-
ing a BN-ProSpec analyzer (Dade Behring BN-
ProSpec). The manufacturer’s reference interval for
healthy subjects is 0.53 to 0.95 mg/L. Assay sensitiv-
ity was 0.005 mg/L; intra-assay and interassay coef-
ficients of variation were 2% and 3.6%, respectively.
Analyses in the Second Cohort
The cJCr and ECr methods when bilirubin 171
mol/L were used to measure serum creatinine, and
the same methodology was used to measure CysC.
The C51Cr-EDTA was performed by sampling blood
after intravenous injection of tracer at 2, 4, and 6 hours.
GFR was calculated using the slope-intercept technique,
correcting for body surface area, and the fast exponen-
tial curve recommended by the British Nuclear Medi-
cine Society guidelines (28).
Cr-based GFR was calculated using the four vari-
able MDRD formulas, which are considered the best
in adults (12,29) and in cirrhosis (11,20): GFR (mL/min
per 1.73 m2)  186  (Cr, using the automated com-
pensated [rate blanked] kinetic Jaffe, in mol/L per
88.4)1.154  (age in years)0.203  0.742 (if female) 
1.210 (if African American). Body weight is not re-
quired because the results are normalized to 1.73 m2
body surface area.
The two CysC-GFR formulas were: Hoek formula:
GFR  4.32  80.35  1/CysC in mg/L (22), and
Larsson formula: GFR  77.239  CysC in mg/
L1.2623 (21). To convert Cr and Bil in mg/dl to
mol/L, we multiplied by 88.4 and 17.1, respectively.
Statistical Analyses
All of the data were analyzed using Medcalc soft-
ware (Mariakerke, Belgium). Normality was assessed
with the Kolmogorov-Smirnov test. Quantitative vari-
ables were expressed as the mean values  SD when
parametric or as median values (range) when non-
parametric. Before multiple parametric comparisons,
the Levene’s Test for equality of variances was per-
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formed. Parametric data were compared using un-
paired t tests and ANOVA tests and nonparametric
data by the Mann-Whitney’s and Kruskal-Wallis tests.
For parametric post tests pairwise subgroup compar-
ison a Student-Newman-Keul’s test was used, and the
Bonferroni correction was used for nonparametric
comparisons. Nonparametric correlations were eval-
uated by Spearman, and parametric ones were eval-
uated by Pearson correlation. The chi-square test and
Fischer’s exact test (when the total number of obser-
vations was 20) were used as qualitative tests.
Bland and Altman analysis (30) and the concordance
correlation coefficient (31) were used to evaluate agree-
ment. Significance testing was two-sided and set to0.05.
Results
Comparison of Serum Cystatin C with Different
Serum Creatinine Measurements
There were 65 patients with cirrhosis (60%male) with
254 blood samples (Table 1). Median values of bilirubin
and INR were 166 mol/L (range, 8 to 913; 95% CI, 149
to 192) and 1.8 (range, 1 to 8; 95% CI, 1.6 to 1.9), respec-
tively. ThemedianmJCr, cJCr, ECr, and JCr values were
110 mol/L (range, 56 to 1280; 95% CI, 104 to 122), 81
mol/L (range, 36 to 1339; 95% CI, 75 to 87), 74 mol/L
(range, 35 to 1146; 95% CI, 70 to 79), and 94 mol/L
(range, 40 to 1212; 95% CI, 87 to 99), respectively (all P
0.001). The median CysC value was 1.14 mg/dl (range,
0.3 to 4.8; 95% CI, 104 to 122) (Table 1). Correlations
between CysC and the four Cr measurements methods
were reasonable being 0.72, 0.71, 0.72, and 0.72, respec-
tively, for JCr, cJCr, ECr, and mJCr (all P  0.001).
Relationship of Serum Bilirubin to Serum Cystatin C
The groups were subdivided according to bilirubin
values: (1) Bil 100 mol/L (n  60, 23.6%); (2)
between 100 and 199 mol/L (n  89, 35%); (3) be-
tween 200 and 399 mol/L (n  57, 22.4%); or (4)
400 mol/L (n  48, 18.9%). The median values for
mJCr, cJCr, ECr, JCr, and CysC according to bilirubin
concentrations are shown in Table 2. Comparisons of
CysC median values between the Bil 400 group and
every other group were significant (P  0.0001 for Bil
100; P  0.0001 for Bil 100 and 200; and P  0.04
for 200 and 400).
The correlation between CysC and bilirubin was poor
(r 0.42, P 0.001). Dilution/titration analysis showed
that serum CysC concentration was not influenced by
bilirubinemia with values as high as 639 mol/L. The
poor correlation of CysC with bilirubin and a much
stronger one with Cr indicate that the increase seen with
CysC as bilirubin increased is mostly influenced by
renal function and not by liver disease. As we previ-
ously reported, correlations between the four different
creatinine and bilirubin measurements were poor (4)
being 0.56, 0.42, 0.38, and 0.44, respectively, for mJCr,
cJCr, ECr, and JCr (all P  0.0001).
Evaluation of 51Cr-EDTA GFR in Cirrhosis and
Comparison with MDRD and Cystatin C GFR
Formulas
In the 74 patients with cirrhosis, the mean MELD
score was 12  5.5, range 2 to 25, and the mean CPT
score was 8.2  2.4, range 5 to 14 (Child A/B/C,
22/27/25). Liver disease etiology was: alcohol, 12;
viral hepatitis (B/C), 28; cryptogenic/nonalcoholic-
Table 1. Characteristics of 65 patients with cirrhosis (254 samples) at the Royal Free Hospital
Characteristics Patients with Cirrhosis(n  65)
Samples
(n  254)
Age (yrs) 51 (26 to 92)
Gender (female/male) 26/39
Cause of liver disease (n [%])
alcohol 21 (32)
viral (hepatitis B or C) 17 (26)
autoimmune 1 (2)
cryptogenic/NASH 8 (12)
PBC/PSC 9 (14)
others 9 (14)
MELD (using the mJCr) 24 (7 to 43)
INR (n.r. 0.8 to 1.2) 1.8 (1 to 8)
Bilirubin (mol/L) (n.r.18) 166 (8 to 913)
mJCr (mol/L) (n.r. 49 to 120) 110 (59 to 1.280)
cJCr (mol/L) 81 (36 to 1.339)
ECr (mol/L) 74 (35 to 1.146)
JCr (mol/L) 94 (40 to 1.212)
CysC (mg/dl) (n.r. 0.53 to 0.95) 1.14 (0.31 to 4.84)
All of the values are expressed as medians (range) or number (%). MELD, model for end stage liver disease; NASH,
nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; n.r., normal range.
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steatohepatitis, 13; primary biliary cirrhosis/primary
sclerosing cholangitis, 14; autoimmune hepatitis, 3;
and other, 4. Fifteen patients (20.3%) had HCC. Me-
dian Bil was 38 mol/L (range, 6 to 957).
51Cr-EDTA varied between 15 and 156 ml/min per
1.73 m2. The patients were classified into two groups:
51Cr-EDTA more (n  48) or less (n  26) than 70
ml/min per 1.73 m2, similar to a previous publication
(32) (Table 3). The median creatinine and cystatin C
values differed significantly, both being increased in the
group with GFR 70 ml/min per 1.73 m2 (P  0.0001).
The liver-related variables that were significantly
different between these groups were encephalopathy,
which was worse, and lower levels of both transami-
nases, in the GFR group 70 ml/min per 1.73 m2.
The 74 patients were also subdivided according to
CPT stage (A/B/C); without significant differences
for Cr, CysC, or GFR measured by 51Cr-EDTA,
MDRD, Larsson, and Hoek (Table 4). Correlations of
the single values of Cr, CysC, and 51Cr-EDTA with
bilirubin were NS.
Correlation between 51Cr-EDTA and MDRD was
moderately good (r  0.72; 95% CI, 0.59 to 0.81; P 
0.0001), whereas between 51Cr-EDTA and Larsson and
Hoek it was not (r  0.46; 95% CI, 0.25 to 0.62; P 
0.0001; and r  0.49; 95% CI, 0.29 to 0.64; P  0.0001,
respectively). Overall agreement with 51Cr-EDTA was
better for MDRD than for CysC formulas (concordance
correlation coefficient: MDRD 0.61; 95% CI, 0.47 to 0.71;
Larsson, 0.38; 95% CI, 0.20 to 0.52; and Hoek, 0.46; 95%
CI, 0.27 to 0.61). Separating patients into those with
ascites and those without, the correlations between the
single CysC values, Hoek, or Larsson formulas and
51Cr-EDTA GFR were better in those without ascites
than with ascites, being 0.76 versus 0.52 (P  NS), 0.75
versus 0.31 (P 0.0001), and 0.72 versus 0.28 (P 0.0002),
respectively. The correlations for Cr did not differ sig-
nificantly in the two groups, for neither the single values
nor the estimated GFR values using theMDRD formula.
The latter findings suggest that ascites may significantly
influence the estimated GFR when the CysC formulas
are used but not the Cr formula.
Degree of Agreement between Different Formulas for
GFR in Cirrhosis
The differences between true GFR and eGFRs were
significantly different (F  3.38, P  0.01) (Figure 1). In
a pairwise comparison, differences between 51Cr-EDTA
and MDRD and 51Cr-EDTA and Larsson were signifi-
cant (P 0.05 for each) but not between 51Cr-EDTA and
Hoek (P 0.05). Bland-Altman plots (Figure 2) showed
that the most accurate method was Hoek, and the most
precise method was MDRD. However, both methods
overestimated GFR in comparison with 51Cr-EDTA es-
pecially for values 70 ml/min per 1.73 m2, and thus
neither CysC GFR formula had good accuracy.
Multivariate Analyses and Evaluation of Improved
Accuracy of Modified GFR Formulas
We performed a stepwise multivariate linear regres-
sion analysis of liver parameters in two analyses using
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Cr andCysC separately.With creatinine 51Cr-EDTA, the
factors used in stepwise order were: age, gender, CPT
score, albumin, bilirubin, ascites, encephalopathy, inter-
national normalized ratio, platelets, aspartate amino-
transferase, alanine aminotransferase, C-reactive pro-
tein, and the presence of HCC. Partial correlations and
relative P values are shown in Table 5.
Independently associated factors were included in
GFR estimation: GFR (ml/min per 1.73 m2)  156 
(0.53  Cr in mol/L)  16.3 (if female)  (2.79  CPT
score), andR2 0.62, F-ratio 41.2 (P 0.001). Next we
tested CysC using the same factors as for Cr (Table 5).
The resulting equation was: GFR (ml/min per 1.73
m2)  129.71  (37.16  CysC)  17.88 (if moderate/
severe ascites), and R2 0.45, F-ratio 29.2 (P 0.001).
Evaluation of New Derived GFR Formulas in Cirrhosis
Using the Bland-Altman analysis, the two new for-
mulas were more accurate compared with the MDRD,
Larsson, and Hoek formulas. The new Cr-eGFR was
Table 3. Characteristics of patients with cirrhosis assessed for liver transplantation and GFR measured by
51Cr-EDTA
Characteristic Total (n  74) GFR  70 (n  48) GFR  70 (n  26) P
Age (yrs) 49 (9.2) 49 (9.8) 50 (8.3) 0.7
Gender (female/male) 28/46 10/16 18/30
Race
white 61 39 22
black 2 2 0
Indian 11 7 4
Weight (kg) 77 (13.9) 76.5 (12.6) 78 (16.2) 0.6
Height (cm) 170 (8) 170 (8) 169 (8) 0.6
Body surface area (m2) 26.5 (4.5) 1.86 (0.19) 1.94 (0.2) 0.1
CPT score 8.2 (2.4) 8.1 (2.6) 8.4 (2.2) 0.6
MELD score 12 (5.5) 10.7 (4.6) 15.5 (5.8) 0.0003a
Creatinine (mol/L) 67.5 (28 to 234) 64 (28 to 90) 109 (53 to 234) 0.0001a
Cystatin C (mg/dl) 0.83 (0.36 to 2.9) 0.81 (0.3 to 1.0) 1.11 (0.5 to 2.9) 0.0001a
C51Cr-EDTA (ml/min
per 1.73 m2)
81.7 (30.8) 100 (17.8) 47.6 (17.5)
Ascites
not present or mild
to moderate (n
[%])
57 (77) 41 (85) 16 (62) 0.001a
severe 17 (23) 7 (15) 10 (38) 0.6
Encephalopathy
not present (n [%]) 42 (57) 32 (67) 10 (38) 0.001a
mild to moderate 24 (32) 10 (21) 14 (54) 0.5
severe 8 (11) 6 (12) 2 (8) 0.2
Bilirubin (mol/L)
(n.r. 18)
38 (6 to 957) 54 (6 to 277) 35 (7 to 957) 0.1
AST (UI/L) (n.r. 19) 69.5 (17 to 266) 76 (27 to 266) 56 (17 to 222) 0.02a
ALT (UI/L) (n.r. 23) 49.5 (11 to 508) 58 (15 to 225) 38 (11 to 508) 0.01a
Albumin (mg/L) (n.r.
36 to 50)
33.8 (5.8) 33.5 (6.2) 34.2 (5.1) 0.6
Prothrombin time (sec) 18.7 (12 to 39) 18.7 (12 to 39) 19 (13 to 25) 0.9
INR (n.r 0.0.8 to 1.2) 1.4 (0.9 to 3.2) 1.4 (0.9 to 3.2) 1.4 (1 to 2) 0.9
CRP (mg/L) (n.r.
0.0.06 to 8)
5.5 (1 to 80) 8 (1 to 80) 4.5 (1 to 64) 0.3
Platelets (n.r. 0.136 to
423/nl)
97.5 (21 to 917) 92.5 (33 to 917) 120 (21 to 328) 0.08
All of the values are expressed as the medians (range), means ( SD), or numbers (%). The P values are for
comparisons between the GFR subgroups (more than 70 or less than 70). AST, aspartate aminotransferase; ALT, alanine
aminotransferase; INR, international normalized ratio; CRP, C-reactive protein; MELD, model for end stage liver
disease; n.r., normal range.
aStatistically significant results.
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more precise than the new CysC-eGFR (Figure 2). We
further evaluated the accuracy of the new eGFR for-
mulas using a method proposed by the National Kid-
ney Foundation (8) that measures the percentage of
GFR estimates that fall within 10, 30, and 50% above
or below the measured GFR (P10, P30, and P50, re-
spectively). The new Cr-eGFR formula was the most
accurate (Table 6). When the same evaluations were
performed in the subgroup of patients with the true
GFR of less than 70 ml/min per 1.73 m2, P10, P30 and
P50 were 15, 48, and 70% for the new Cr-eGFR; 15, 44,
and 66% for the new CysC-eGFR; 23, 42, and 53% for
Hoek; and 15, 46, and 73% for MDRD.
Discussion
We used two cohorts of patients with cirrhosis. In the
first cohort we assessed correlations of serumCysCwith
different measurement methods for Cr and whether
worsening liver function expressed by increasing biliru-
bin concentrations affected its values. In the second
cohort we assessed whether CysC and its derived GFR
equations performed better in comparison with Cr and
its derived GFR equations, compared with 51Cr-EDTA
GFR.
Bil correlated poorly with CysC in both cohorts,
whereas CysC was strongly correlated with Cr. Sim-
ilar to our results, initial studies assessing the inter-
ference of Bil with CysC measurement showed that
results were not influenced by hyperbilirubinaemia
up to 700 mol/L (33). There were no significant
differences across the CPT stage, at variance with a
previous report of only 25 patients (18).
Both CysC formulas significantly overestimated renal
clearance compared with C51Cr-EDTA. Multivariate se-
verity of the CPT score added accuracy to a Cr-based
GFR formula and the presence of ascites to a CysC-
based formula. Interestingly it also showed that female
gender is still an important factor affecting the Cr-based
formula (7) but not the CysC-based formula. The new
Cr formula resulted the best in comparison with C51Cr-
EDTA rather than MDRD, Hoek, and the new CysC
formulas.
The four-variable MDRD formula is derived from
large patient cohorts without liver disease (8) but has
Table 4. Comparison between serum creatinine and cystatin C, and the various GFR formulae grouped according to CPT
stage
CPT Class A CPT Class B CPT Class C P
Cystatin C 0.84 (0.47 to 2.9) 1.01 (0.39 to 2.67) 0.82 (0.36 to 1.27) 0.5
Creatinine 69.5 (48 to 234) 67 (40 to 228) 68 (28 to 150) 0.7
C51Cr-EDTA 84.8 (38) 83.2 (32) 77.4 (21.8) 0.4
MDRD 96.7 (36.1) 95 (36.8) 110 (48.7) 0.7
Larsson 89.3 (41.4) 105 (53.7) 106 (44) 0.4
Hoek 84.2 (33.5) 95.9 (41.7) 97.9 (32.1) 0.4
All of the values are expressed as medians (range) or means ( SD).
Figure 1. | Scatter plot diagram showing GFR in each of 74 patients with cirrhosis measured with the gold standard method 51Cr-EDTA
and estimated methods using creatinine (MDRD) or cystatin C (Larsson and Hoek). The mean for each method is represented by a line.
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Figure 2. | Bland-Altman plots comparing GFR measurements with 51Cr-EDTA (gold standard method) with two creatinine-based
formulas of estimated GFR (MDRD and new Cr eGFR) and three cystatin C-based formulas (Larsson, Hoek, and new CysC eGFR).
Table 5. Partial correlations of the variables evaluated with respect to associations with 51Cr-EDTA GFR in 74 patients
with cirrhosis
Model for Creatinine Model for Cystatin C
r P r P
Creatinine 0.80 P  0.001a
Cystatin C 0.64 P  0.001a
Age 0.03 P  0.7 0.09 P  0.4
Albumin 0.03 P  0.7 0.05 P  0.6
ALT 0.17 P  0.1 0.008 P  0.9
AST 0.02 P  0.8 0.09 P  0.4
Ascites 0.16 P  0.1 0.33 P  0.001a
Bilirubin 0.16 P  0.1 0.11 P  0.3
CPT score 0.22 P  0.003a 0.11 P  0.3
CRP 0.21 P  0.07 0.07 P  0.5
HCC 0.07 P  0.5 0.06 P  0.5
INR 0.17 P  0.1 0.03 P  0.7
Gender 0.25 P  0.001a 0.11 P  0.3
Platelets 0.18 P  0.1 0.09 P  0.4
AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; CRP, C-reactive
protein.
aVariables included in the final multivariate model.
90 Clinical Journal of the American Society of Nephrology
only been validated in one large cohort of patients
with cirrhosis (11). The CysC equations have also
been derived from nonliver disease populations (93
patients with diabetes, vasculitis, and glomerulopa-
thies (22) and 100 patients of unspecified cause [21])
and only evaluated in 44 patients with cirrhosis (20).
In our patients with cirrhosis, the Hoek CysC for-
mula performed better than the Larsson, having less
bias, and was better than the MDRD. However, the
MDRD was more precise than both the Hoek and
Larsson formulas. Nevertheless, each formula overes-
timated renal clearance significantly in comparison
with C51Cr-EDTA.
There is only one published study similar to ours
(20), evaluating retrospectively 44 patients with cir-
rhosis, comparing CysC-based (Larsson and Hoek)
and Cr-based (MDRD and C-G) formulas with inulin
clearance as the gold standard. The median CPT score
was similar, but with a lower median Bil (29 mol/L)
but higher mean Cr (94.5 mol/L) and mean CysC
(1.21 mg/dl). All eGFR formulas overestimated the
true GFR significantly. CysC-based formulas per-
formed similarly, and both were more precise than
Cr-based formulas. However, accuracies measured
with the relative P10, P30, and P50 were surprisingly
very low; for the best P10 it was 2.3%, for the best P30
it was 13.6%, and for the best P50 it was 20.5%. These
differences are greater than in our cohort and than in
patients with chronic kidney disease, in whom the
MDRD formula was validated; the P30 accuracy was
92%, and the P50 accuracy was 98% (8). The accuracy
of MDRD in our cohort with cirrhosis was 64% and
81%, similar to the reference study (8). For our new Cr
eGFR formulas, the accuracy was 78 and 89%, al-
though the accuracy was reduced in the subgroup
with a true GFR 70 ml/min per 1.73 m2, in which
the P10, P30, and P50 were 15, 48, and 70%, respec-
tively, for the new Cr eGFR and 15, 44, and 66%,
respectively, for the new CysC eGFR, with 23, 42, and
53%, respectively, for Hoek, and 15, 46, and 73%,
respectively, for MDRD. This clearly demonstrates
that in cirrhosis the relative accuracies for estimating
GFR drop with decreasing renal function. Although
these values are far better than the very low values
reported by Poge et al. (20), our new formulas cannot
be used in clinical practice but demonstrate that pa-
rameters of liver function improve standard formulas
and need validation in large cohorts. Gonwa et al. (11)
reported a P30 accuracy of 67% for the four-factor
MDRD, a finding very similar to our result of 64%,
which was in a much smaller cohort. This suggests
that our cohort is a representative one for cirrhosis. In
patients with chronic kidney disease even with a very
low GFR (30 ml/min per 1.73 m2), P30 and P50 were
much better at 69 and 88%, respectively, for each of
the four-, five-, and six-variable MDRD formulas (34),
showing that patients with cirrhosis are a special case
when GFR is low.
A limitation of this study was that the method used
as the gold standard for measuring GFR has not been
extensively validated in patients with ascites. How-
ever, we used the three-sample method to measure
Cr-EDTA clearance, which is more accurate than the
one-sample method.
Conclusions
This study shows that serum CysC does not pro-
vide a sufficient improvement over serum Cr in re-
flecting renal function in patients with cirrhosis, using
the most widely used formulas to estimate GFR. A
new GFR formula for Cr improved accuracy in esti-
mating GFR by including the CPT score (i.e. an index
of liver dysfunction) as well as female gender.
Because existing CysC-eGFRs do not reflect true
GFR with great accuracy in cirrhosis and because
even the new formulas of eGFR that we derived,
although better than existing formulas, still did not
have a good correlation with a direct method of GFR
measurement, more studies are required to elucidate
the usefulness of CysC as a marker of GFR and to
develop accurate eGFR formulas. In cirrhosis there
needs to be good evidence that CysC has significant
advantages over Cr to recommend the use of CysC.
This is particularly so when the GFR falls below
70 ml/min per 1.73 m2, which is known to have an
adverse effect on prognosis both before (1,35,36) and
after (2,37) liver transplantation.
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